I agree sage. Some said no trials would begin this year. Then they said only 2 will start...where is the Rett? When the Rett trial is announced they will say what about MS and ALS?
The Oct. 26 CTAD data will be interesting...particularly when it is compared to Biogen's data. But even then the patient numbers are small. However in a 2a trial you are looking for signs of efficacy. These were found...and the longer term signs of efficacy will be even more important IMO. And the genetic variant analysis adds a whole new element of interest to the 2b/3 trial.
I am confident both the industry and wise investors are beginning to have Anavex on their radar.
No trials have started. Enrolling a first patient doesn't count in my view and that's only one trial. Nothing from either Rett or PD. Until Anavex starts dosing patients then and only then can anyone say "the trials have started." I will grant you that enrolling patients is a good sign.
News 
Market Data 
Discover 
AI
